Richard M Dunham
Overview
Explore the profile of Richard M Dunham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dashti A, Sukkestad S, Horner A, Neja M, Siddiqi Z, Waller C, et al.
Nat Med
. 2023 Oct;
29(10):2535-2546.
PMID: 37783968
The main barrier to HIV cure is a persistent reservoir of latently infected CD4 T cells harboring replication-competent provirus that fuels rebound viremia upon antiretroviral therapy (ART) interruption. A leading...
2.
Falcinelli S, Peterson J, Turner A, Irlbeck D, Read J, Raines S, et al.
J Clin Invest
. 2022 Apr;
132(8).
PMID: 35426377
Latency reversal strategies for HIV cure using inhibitor of apoptosis protein (IAP) antagonists (IAPi) induce unprecedented levels of latent reservoir expression without immunotoxicity during suppressive antiretroviral therapy (ART). However, full...
3.
Bricker K, Obregon-Perko V, Williams B, Oliver D, Uddin F, Neja M, et al.
J Virol
. 2022 Mar;
96(7):e0169921.
PMID: 35293766
The "shock and kill" strategy for HIV-1 cure incorporates latency-reversing agents (LRA) in combination with interventions that aid the host immune system in clearing virally reactivated cells. LRAs have not...
4.
Swainson L, Sharma A, Ghneim K, Pereira Ribeiro S, Wilkinson P, Dunham R, et al.
JCI Insight
. 2022 Feb;
7(5).
PMID: 35104248
Type I IFNs (TI-IFNs) drive immune effector functions during acute viral infections and regulate cell cycling and systemic metabolism. That said, chronic TI-IFN signaling in the context of HIV infection...
5.
Mavigner M, Liao L, Brooks A, Ke R, Mattingly C, Schoof N, et al.
J Virol
. 2021 Feb;
95(8).
PMID: 33568515
Inducing latency reversal to reveal infected cells to the host immune system represents a potential strategy to cure HIV infection. In separate studies, we have previously shown that CD8 T...
6.
Dashti A, Waller C, Mavigner M, Schoof N, Bar K, Shaw G, et al.
J Virol
. 2020 Aug;
94(21).
PMID: 32817214
The "shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strategy involves latency reversal followed by immune-mediated clearance of infected cells. We have previously shown that activation of the noncanonical NF-κB...
7.
Kazmierski W, Xia B, Miller J, De la Rosa M, Favre D, Dunham R, et al.
J Med Chem
. 2020 Feb;
63(7):3552-3562.
PMID: 32073266
We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class through the affinity selection of a previously unreported indole-based DNA-encoded library (DEL). The DEL exemplar, spiro-chromane , had...
8.
Nixon C, Mavigner M, Sampey G, Brooks A, Spagnuolo R, Irlbeck D, et al.
Nature
. 2020 Jan;
578(7793):160-165.
PMID: 31969707
Long-lasting, latently infected resting CD4 T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy...
9.
Vujkovic-Cvijin I, Swainson L, Chu S, Ortiz A, Santee C, Petriello A, et al.
Cell Rep
. 2015 Nov;
13(8):1589-97.
PMID: 26586432
Gut microbes can profoundly modulate mucosal barrier-promoting Th17 cells in mammals. A salient feature of HIV/simian immunodeficiency virus (SIV) immunopathogenesis is the loss of Th17 cells, which has been linked...
10.
Somsouk M, Dunham R, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, et al.
PLoS One
. 2014 Dec;
9(12):e116306.
PMID: 25545673
Unlabelled: The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation...